Add-on azithromycin reduces sputum cytokines in non-eosinophilic asthma: an AMAZES substudy.

Shukla, SD; Taylor, SL; Gibson, PG; Barker, D; Upham, JW; Yang, IA; Reynolds, PN; Hodge, S; James, AL; Rogers, GB; Simpson, JL

Add-on azithromycin reduces sputum cytokines in non-eosinophilic asthma: an AMAZES substudy.

Shukla, SD Taylor, SL Gibson, PG Barker, D Upham, JW Yang, IA Reynolds, PN Hodge, S James, AL Rogers, GB Simpson, JL

Permalink

Publisher:: BMJ PUBLISHING GROUP
Publication Type:: Journal Article
Citation:: Thorax, 2021, 76, (7), pp. 733-736
Issue Date:: 2021-07

Closed Access

	Filename	Description	Size
	733.full.pdf		794.31 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Shukla, SD
dc.contributor.author	Taylor, SL
dc.contributor.author	Gibson, PG
dc.contributor.author	Barker, D
dc.contributor.author	Upham, JW
dc.contributor.author	Yang, IA
dc.contributor.author	Reynolds, PN
dc.contributor.author	Hodge, S
dc.contributor.author	James, AL
dc.contributor.author	Rogers, GB
dc.contributor.author	Simpson, JL
dc.date.accessioned	2021-09-06T05:28:28Z
dc.date.available	2020-12-07
dc.date.available	2021-09-06T05:28:28Z
dc.date.issued	2021-07
dc.identifier.citation	Thorax, 2021, 76, (7), pp. 733-736
dc.identifier.issn	0040-6376
dc.identifier.issn	1468-3296
dc.identifier.uri	http://hdl.handle.net/10453/150362
dc.description.abstract	Add-on azithromycin (AZM) significantly reduces exacerbations in poorly controlled asthma irrespective of disease phenotype. In a predefined substudy of the original AMAZES protocol (500 mg, three times a week for 48 weeks), we report that AZM treatment reduces key sputum inflammatory proteins (interleukin (IL)-6, IL-1β and extracellular DNA), which is more evident in non-eosinophilic asthma (NEA). Moreover, AZM reduced <i>Haemophilus influenzae</i> load only in NEA. Our data support the anti-inflammatory effects of AZM in poorly controlled asthma. Prospective studies are required to identify patients that derive greatest benefit from AZM add-on therapy.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	BMJ PUBLISHING GROUP
dc.relation.ispartof	Thorax
dc.relation.isbasedon	10.1136/thoraxjnl-2020-216331
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	1103 Clinical Sciences
dc.subject.classification	Respiratory System
dc.subject.mesh	Anti-Bacterial Agents
dc.subject.mesh	Asthma
dc.subject.mesh	Azithromycin
dc.subject.mesh	Cytokines
dc.subject.mesh	Humans
dc.subject.mesh	Prospective Studies
dc.subject.mesh	Sputum
dc.subject.mesh	Sputum
dc.subject.mesh	Humans
dc.subject.mesh	Asthma
dc.subject.mesh	Azithromycin
dc.subject.mesh	Cytokines
dc.subject.mesh	Anti-Bacterial Agents
dc.subject.mesh	Prospective Studies
dc.subject.mesh	Anti-Bacterial Agents
dc.subject.mesh	Asthma
dc.subject.mesh	Azithromycin
dc.subject.mesh	Cytokines
dc.subject.mesh	Humans
dc.subject.mesh	Prospective Studies
dc.subject.mesh	Sputum
dc.title	Add-on azithromycin reduces sputum cytokines in non-eosinophilic asthma: an AMAZES substudy.
dc.type	Journal Article
utslib.citation.volume	76
utslib.location.activity	England
utslib.for	1103 Clinical Sciences
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
utslib.copyright.status	closed_access	*
pubs.consider-herdc	false
dc.date.updated	2021-09-06T05:28:27Z
pubs.issue	7
pubs.publication-status	Published
pubs.volume	76
utslib.citation.issue	7

Abstract:

Add-on azithromycin (AZM) significantly reduces exacerbations in poorly controlled asthma irrespective of disease phenotype. In a predefined substudy of the original AMAZES protocol (500 mg, three times a week for 48 weeks), we report that AZM treatment reduces key sputum inflammatory proteins (interleukin (IL)-6, IL-1β and extracellular DNA), which is more evident in non-eosinophilic asthma (NEA). Moreover, AZM reduced Haemophilus influenzae load only in NEA. Our data support the anti-inflammatory effects of AZM in poorly controlled asthma. Prospective studies are required to identify patients that derive greatest benefit from AZM add-on therapy.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/150362